This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Immunome’s 8K filing here.
About Immunome
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Recommended Stories
- Five stocks we like better than Immunome
- How to Find Undervalued Stocks
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- 3 Fintech Stocks With Good 2021 Prospects
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- P/E Ratio Calculation: How to Assess Stocks
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
